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The SARS-CoV-2 pandemic has caused unprecedented global health and economic crises. Several vaccine 
approaches and repurposed drugs are currently under evaluation for safety and efficacy. However, none of them 
have been approved for COVID-19 yet. Meanwhile, several nMAbs targeting SARS-CoV-2 spike glycoprotein are 
in different stages of development and clinical testing. Preclinical studies have shown that cocktails of potent 
nMAbs targeting the receptor binding site of SARS-CoV-2, as well as broad-nMAbs targeting conserved regions 
within the virus spike, might be effective for the tr atment and prophylaxis of COVID-19. Currently, several clinical 
trials have started to test safety, tolerability, PKs and efficacy of these nMAbs. One paramount limitation for the use 
of nMAbs in clinical settings is the production of large amounts of MAbs and the high costs related to it. 
Cooperation among public and private institutions coupled with speed of development, rapid safety evaluation and 
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The SARS-CoV-2 pandemic has caused unprecedented global health and economic crises. Several vaccine appro ches and repurposed 9 
drugs are currently under evaluation for safety andefficacy. However, none of them have been approved for COVID-19 yet. 10 
Meanwhile, several nMAbs targeting SARS-CoV-2 spike glycoprotein are in different stages of development a d clinical testing. 11 
Preclinical studies have shown that cocktails of potent nMAbs targeting the receptor binding site of SAR -CoV-2, as well as broad-12 
nMAbs targeting conserved regions within the virus spike, might be effective for the treatment and prophylaxis of COVID-19. 13 
Currently, several clinical trials have started to test safety, tolerability, PKs and efficacy of these nMAbs. One paramount limitation 14 
for the use of nMAbs in clinical settings is the production of large amounts of MAbs and the high costs related to it. Cooperation 15 
among public and private institutions coupled with speed of development, rapid safety evaluation and efficacy, and early planning for 16 
scale-up and manufacture will be critical for the control of COVID-19 pandemic. 17 
 18 
 19 
1. Introduction 20 
 21 
In the last two decades, three different coronaviruses (CoVs) caused zoonotic outbreaks in humans: severe acute respiratory syndrome 22 
CoV (SARS-CoV, from now referred as SARS1) [1], Middle East respiratory syndrome CoV (MERS) [2] and more recently, severe 23 
acute respiratory syndrome CoV-2 (SARS-CoV-2, from now referred as SARS2) [3–6]. Compared to endemic human CoVs these 24 
three novel CoVs cause more severe acute respiratory disease and are associated with high fatality rates (9.6%, 34.4% and 0.6-3%, 25 
respectively) [7,8]. Although SARS2 has lower fatality rates compared to SARS1 and MERS, it spread much faster [9–11]. For that 26 
reason, the absolute number of deaths up to August 2020 is higher for SARS2 (776,157) compared to SARS1 (794) and MERS (858) 27 
[12]. Among patients infected with SARS2, the progression of disease is highly variable. Roughly, eighty percent of people that 28 
become infected with SARS2 develop mild or no symptoms; whereas the remaining 20% develop moderate to s vere disease (termed 29 










hypertension, diabetes and obesity among those with higher risk to develop respiratory failure and die. SARS2 pathogenicity, results 31 
from an acute excessive virus replication followed by an uncontrolled inflammation and an exacerbated immunity, explaining why in 32 
some patients, disease severity increases when viral load decreases [16,17]. 33 
SARS2 is a large enveloped RNA virus, containing a single-stranded, positive-sense RNA genome that encodes for a series of 34 
structural and non-structural proteins, as well as a group of accessory genes. The envelope spike (S) protein of CoVs is a trimeric type-35 
1 integral membrane protein and class-1 fusion protein which possess 3 copies of an N-terminal subunit (S1) that mediates receptor 36 
attachment and 3 copies of a C-terminal subunit (S2) that mediates virus-cell membrane fusion. The S1 subunit contains 4 domains 37 
(A-D), being A (N-terminal) and B (receptor binding domain or RBD) the most relevant from an immunological point of view. The 38 
RBD of the spike glycoprotein (S) is poorly conserved among CoVs and, as a result, host receptor usage varies among different CoVs. 39 
Although SARS2 is closer to bat-SL-CoVZC45 and bat-SL-CoVZXC21 at the whole-genome level, the RBD of SARS2 is closer to 40 
that of SARS1 [18]. Interestingly, the RBD of SARS1 and SARS2 are 74% identical and both viruses use angiotensin-converting 41 
enzyme 2 (ACE2) present in the surface of target cells as receptor for docking and entry [3,18–21]. SARS1 and SARS2 RBD is 42 
subdivided in an N-terminal subdomain (RBD-NTD) and the receptor binding site (RBS). The homology of RBD-NTD and RBS 43 
between these two viruses is 83% and 50%, respectively. Post-attachment events are dependent on cellular proteases, such as 44 
transmembrane protease serine 2 (TMPRSS2) which cleave the spike protein and initiate a variety of conformational changes that are 45 
important for membrane fusion and entry.  46 
SARS2 spike glycoprotein is the main target of neutralizing antibodies (NAbs) and several neutralizing monoclonal antibodies 47 
(nMAbs) targeting different epitopes within the virus spike have been recently described. Moreover, several preclinical studies have 48 
demonstrated that SARS2 nMAbs can suppress virus replication and disease severity in different animal odels. In the absence of an 49 
effective treatment for COVID-19, passive immunization with nMAbs has recently gained interest as a therapeutic approach to reduce 50 
SARS2 impact in public health worldwide. In this article, I discuss advantages and challenges related to the use of nMAbs for 51 
treatment and prevention of COVID-19. References for this article were identified through searches of PubMed with search terms 52 
“SARS-CoV-2”, “COVID-19”, “neutralizing antibodies”, “monoclonal antibodies”, “therapy”, “prophylaxis” from December 2019 to 53 
August 2020. Additionally, the terms “SARS-CoV-2”, “COVID-19” and “monoclonal antibodies”, were searched at 54 
ClinicalTrials.gov. The final references were selected on the basis of relevance to the particular scope of this Review. 55 
 56 
 57 
2. Main Text 58 
 59 











In COVID-19 patients, viral load peak occurs concomitantly or shortly after symptoms onset. After peaking, viral load decreases 62 
slowly and is detectable for up to 4 weeks [22,23]. However, infective virus has been isolated from the upper respiratory tract only 63 
within the first week after symptom onset [22]. As the virus replicates, the adaptive immunity is stimulated to generate cellular 64 
responses and antibodies (Abs), including NAbs in the majority of SARS2 infected symptomatic individuals [24]. IgM, IgG and IgA 65 
antibodies directed to SARS2 external S and internal N proteins develop within the first week after symptoms onset and peak two 66 
weeks after symptoms onset [22,23]. In 50% of individuals, seroconversion occurs one week after symptos nset and 100% of 67 
individuals seroconvert by the end of the second week after symptom development [22,25–28]. Several studies reported an inverse 68 
correlation between viral loads and SARS2 specific-Abs; however, by the time that Abs develop, viral loads have already started to 69 
decrease indicating that innate and/or cellular adaptive immunity contribute to the initial virus containment [22,23,25]. Additionally, 70 
the Ab response can be weak or absent in asymptomatic or mild infections, suggesting at least a partial control of the virus by innate 71 
or T-cell mediated immunity [29,30]. Paradoxically, several studies have found a positive correlation between specific-Ab titers and 72 
disease severity, suggesting that a robust Ab response alone is insufficient to avoid severe disease and point out that the timing of Ab 73 
development might be crucial for efficient virus contr l [25,27,28,31,32]. The one-week gap between peak viral load and 74 
seroconversion suggests that the Ab response fails to efficiently control virus load during the first two weeks of infection and 75 
consequently, the excessive virus replication within t is period could ignite the inflammatory process a ociated with severe disease. 76 
In addition, a larger antigenic exposure associated with virus replication might provoke the development of higher titers of antibodies 77 
in severe disease outcomes. Alternatively, it has been proposed that antibody dependent enhancement (ADE), a mechanism triggered 78 
by specific Abs, could potentially increase disease severity. ADE has been described for other viruses such as dengue virus (DENV) 79 
and respiratory syncytial virus (RSV) [33–35]. Although, ADE has also been described for SARS1 in vitro and in animal models, 80 
there is no evidence that this might happen in SARS2 infection in humans [36].  81 
Oppositely, observations from several studies underscore a key antiviral effect of Abs, suggesting they might be a key immune 82 
correlate for protection against SARS2 infection: (i) seroconversion occurs in most COVID-19 patients [22,23,25]  (ii) viral loads in 83 
SARS2 infected patients decrease after anti-S IgM and IgG antibodies development [22,23,25] (iii)  memory B cells specific for 84 
SARS2 S antigens have been isolated and characterized from COVID-19 patients [30,37,38] (iv) NAbs induced in macaques after 85 
vaccination protect animals from development of disease after challenge with SARS2 [39] (v) macaques challenged with SARS2 86 
develop a robust NAb response that protects them fro  reinfection after a second challenge [40,41] (vi) passive transfer of anti-87 
SARS2 monoclonal NAb protects animals from disease after challenge with SARS2 [38,42,43]. Furthermore, a meta-analysis from 32 88 
studies of SARS1 and severe influenza virus infection performed by Mair-Jenkins and colleagues showed a significant reduction in 89 










15 severe/ critically ill COVID-19 patients was followed by improvement in the patient clinical status. Interestingly, plasma treated 91 
patients had large reduction in viral loads and most were virus negative 3 days after infusion [45,46].  92 
CoVs S protein and its RBD are highly immunogenic and most infected patients develop both anti-S and anti-RBD antibodies. Earlier 93 
during the pandemic, Hoffmann and colleagues showed that polyclonal Abs present in plasma from SARS1 infected individual could 94 
cross-react with SARS2 [21]. In a similar fashion, the plasma from COVID-19 convalescent patients cross- eact with SARS1, and to a 95 
lesser extent with MERS and common cold CoVs [47]. Although the reactivity of COVID-19 plasmas against endemic CoVs has been 96 
associated with previous encounter to such type of viruses, its reactivity against MERS and SARS1 has proven to be due to cross-97 
reactivity against conserved epitopes within S protein [47]. COVID-19 patients develop anti-S1 and anti-RBD antibodies; however, 98 
antibodies that effectively disrupt the binding of S protein and ACE2 receptor account for a small fraction of them 99 
[30,37,38,42,43,48,49].  100 
 101 
 102 
2.2. Development of neutralizing monoclonal antibodies for COVID-19 103 
 104 
2.2.1. Anti-SARS2 neutralizing monoclonal antibody discovery.  105 
Several monoclonal antibodies (MAbs) targeting the RBS of SARS1 have been described (i.e., CR3014, M396 and S230). Although 106 
these MAbs effectively neutralize SARS1 most of them do not cross neutralize SARS2, due to differences in the primary amino acid 107 
sequence of RBS among these viruses. However, theseobservations supported the discovery and characteriza ion of SARS2 MAbs 108 
from COVID-19 patients. Over the past two decades, ifferent programs from several institutions (i.e., NIAID Center for HIV/AIDS 109 
Vaccine Immunology, Vaccine Research Center, Pandemic Prevention Program (P3) program, etc.) have worked to define the 110 
platforms and enable technology for HIV vaccine development and rapid response to viral pandemics. From those, as well as other 111 
international initiatives, have come teams and technologies that are now responding to the COVID-19 epid mic to isolate SARS2 112 
nMAbs [50]. As a result, several highly potent nMAbs targeting SARS2 RBD and S protein have been isolated using different 113 
approaches (i.e., immortalized EBV memory B cells, Ab isolation from mouse hybridomas, phage display libraries produced from 114 
llama immunized with prefusion-stabilized CoV spikes, direct cloning of Ig-encoding genes from isolated B cells sorted with 115 
fluorescent baits such as RBD and S-protein, microculture and supernatant screening of sorted memory B cells and single B cell NGS 116 
from sorted memory B cells, etc.) [30,37,38,42,43,47–49,51–61]. A description of these Abs can be found in Table 1.  As observed 117 
for SARS1, highly potent nMAbs isolated from COVID-19 convalescent patients targeted the RBS and competed directly with ACE2 118 










despite partial homology between SARS1 and SARS2 RBDs, these domains might be immunologically different, i dicating cross 120 
reactivity could occur within S protein but outside ACE2-binding site [37].  121 
 122 
2.2.2. Avoiding the emergence of virus resistance.  123 
Importantly, as observed earlier for SARS1, escape mutations were rapidly selected when single SARS2 MAbs were tested in vitro 124 
[62]. Furthermore, a natural mutation of SARS2 has now been detected at residue 495 (Y/N), which forms part of the ACE2 binding 125 
epitope. As RNA viruses are known to accumulate mutations over time, a big concern for any antiviral trea ment is the risk for 126 
selection of treatment-induced escape viral-variants. I  this regard, the discovery of novel nMAbs targeting different sites on SARS2 S 127 
protein will be extremely important to counteract the mutational capacity of the virus and avoid the emergence of resistant viral 128 
variants due to the administration of single drug therapy.  129 
One strategy to prevent viral escape would be the use of antibodies targeting highly conserved epitopes on S protein. Toward this goal, 130 
Yuan and colleagues described a cryptic epitope located within the RBD but outside the RBS, which is conserved between SARS1 131 
and SARS2 and is targeted by MAb CR3022 [63]. Interestingly, MAb CR3022, which has been isolated from a SARS1 infected 132 
patient [52] cross-neutralizes SARS2 by a mechanism that does not imply competition with ACE2 [53]. Different groups have isolated 133 
antibodies targeting the RBD-NTD with high neutralizing activity against SARS2. MAb S309, was isolated from immortalized B cell 134 
from a SARS1 infected patient [55]. This nMAb recognizes a glycan-containing epitope that is conserved within different SARS-135 
related CoVs (sarbecovirus). In the second place, Wang and colleagues isolated 47D11 MAb from SARS1 mouse hybridoma [54]. As 136 
it is the case with CR3022, none of these MAbs compete with receptor attachment. More recently, Lv and colleagues described a 137 
novel humanized-nMAb, H014, that prevents attachment of SARS2 to its host cell receptors [64]. In this opportunity, the authors 138 
constructed an antibody library generated from RNAs extracted from peripheral lymphocytes of mice immunized with recombinant 139 
SARS1 RBD and then, they screened the phage antibody library using a SARS2-RBD. As described for S309 and 47D11, H014 binds 140 
to an epitope within the RBD, but different to RBS, which allows these antibodies to cross-neutralize both SARS1 and SARS2. 141 
However, in the case of H014, the interaction betwen the antibody and S protein interferes with receptor binding. In a separate study, 142 
Wec and colleagues screened memory B cells from a SARS1-survivor and found 8 SARS2 cross-reactive MAbs targeting a single 143 
continuous patch in the surface of the RBD [56]. This ighly conserved area which spans from ACE2-binding site to the epitope 144 
recognized by MAb CR3022 explains cross-reactivity found in these set of antibodies. In addition, Wrapp nd colleagues isolated 145 
SARS-VHH-72, a single chain antibody from a llama immunized with prefusion-stabilized SARS1 spike that cross reacted with 146 
SARS2 [57]. SARS VHH-72 prevents the binding of ACE2 through a partially overlapping epitope of MAb CR3022. When two 147 
copies of this VHH were coupled as a bi-valent IgG-Fc fusion (named VHH72-Fc) the construct was also able to neutralize SARS2. 148 










that some residues are indispensable for granting spike stability, mutations at this point would be less frequent and if they occur, they 150 
might have a strong negative impact in viral fitness. For that reason, Abs targeting this particular site of neutralization might be more 151 
resistant to virus escape. Another site of vulnerability targeted by cross-reactive nMAbs consists in the N-terminal region of S1 protein 152 
[47,51,56]. Chi and colleagues described MAb 4A8 targeting this particular region on SARS2 S protein [51]. Finally, Liu and 153 
colleagues isolated potent and diverse nMAbs targetin  several epitopes on SARS2 spike [65]. Apart from those antibodies directed to 154 
the RBD and NTD, the author described two nMAbs targeting novel quaternary epitopes located on top of SARS2 spike.  155 
Expanding the number of potent nMAbs with different specificities against S protein will allow the formulation of more effective 156 
nMAb cocktails; such combination of nMAbs accounting for different specificities may provide a powerful way to minimize 157 
mutational escape by SARS2 [62]. Moreover, the rational development of nMAb cocktails targeting different sites of vulnerability 158 
within the S protein could confer a synergistic neutralizing effect. Anti-SARS2 nMAbs described in Table 1 have been characterized 159 
in detail by in vitro binding affinity, epitope mapping by competition assays, target specificity by cryo-EM and most importantly, for 160 
in vitro and in vivo neutralization, using different platforms. Remarkably, these antibodies have proven to be effective preventing 161 
infection of target cells, and most importantly blunting virus replication and pathogenicity in different animal models (i.e. hu-ACE2 162 
transgenic mice, Syrian golden hamster and non-human primates (NHPs) [38,42,43,49,64,66]. Overall, these studies indicate that 163 
several nMAbs have the potential to be used either prophylactically or therapeutically to avoid and/or c ntrol SARS2 infection.  164 
 165 
2.2.3. Effector mechanism triggered by nMAbs.  166 
IgG contains two antigen combining sites (Fabs) and  Fc region that interacts with various Fc receptors (FcRs) on immune cells. 167 
MAbs differ from antiviral drugs in that in addition to potent viral particle neutralization and high specificity they can engage the host 168 
immune cells (i.e., NK, neutrophils and macrophages) through their FcRs and trigger several immune effctor mechanisms (i.e., 169 
antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and antibody-dependent cellular viral inhibition); 170 
furthermore, MAbs can induce complement-dependent cytotoxicity through their Fc domain [67]. Altogether, these effector functions 171 
triggered by MAbs contribute towards controlling viral replication. In addition, MAbs can bind viral antigens to form immune 172 
complexes (ICs) that enhance antigen presentation and boost endogenous immune responses in a mechanism k own as “vaccine-like 173 
effect” [68]. Different studies have shown that besid  potent neutralization, anti-SARS2 Abs effectively trigger FcR present in 174 
effector cells, providing additional protective mechanisms in vitro and in vivo [39,40,55,60]. These results suggest that Fc engineering 175 
could potentially enhance these antiviral effects as it has been demonstrated for other viral diseases [69]. Even though Fc-FcR 176 
interactions can enhance immunity in a favorable way, they can also lead to disease enhancement. The risks of ADE will need to be 177 
further evaluated for SARS2. Meanwhile, in the context of human studies it would be possible to use engineered MAbs with reduced 178 










mutation at the Fc region of the antibody (L234A/L235A) [70]. By introducing this LALA double mutation within the Fc region of 180 
anti-SARS2 CB6 MAb, Shi and colleagues showed in macaques that the antiviral efficacy of CB6-LALA was not affected [43]. 181 
 182 
 183 
2.3. From the bench to the bedside 184 
 185 
SARS2 has already caused a great impact globally, and it is expected that subsequent waves of infection will hit regions that are 186 
currently recovering from devastating initial COVID-19 outbreaks. In the absence of a vaccine, a high proportion of human global 187 
population might become infected in the next years. Experts in this field have estimated that testing, large scale production and 188 
distribution of an effective vaccine might take from 1 to 2 years [71].  Considering that there is no effective treatment the number of 189 
deaths will also increase exponentially during the next years. Under the current situation, novel preventi e approaches are in great 190 
need. Passive immunization with NAbs has recently gained interest as the most convenient approach to fulfill this gap and reduce 191 
SARS2 impact in public health worldwide [72–74]. The reduction of SARS2 viral load by NAbs, as observed in CP pilot trials suggest 192 
that SARS2 infection in humans can be modulated using passive immunization in clinical settings. Compared to CP, nMAbs can be 193 
thoroughly characterized in vitro. In addition, the ability to control dosing and cocktails composition improves the efficacy of nMAbs 194 
over CP. Furthermore, the use of MAbs with highly potent neutralizing activity can reduce the risks of ADE, compared to the 195 
polyclonal mixture of Abs present in the plasma. Recent studies with patients infected with Ebola highlight the higher efficacy of 196 
nMAbs over CP treatment [75].  The finding that ansuvimab (MAb114) is safe and effective reducing the mortality rate of Ebola virus 197 
disease from 67% to 34%, underscore the potential use of MAb therapy during a deadly infectious disease outbreak [75–77]. For HIV-198 
1, another lethal pandemic virus, it took more than 30 years to discover effective nMAbs capable of neutralizing most circulating HIV-199 
1 isolates [78–82]. Following a detailed molecular characterization and efficacy pre-clinical trials, only few of these antibodies have 200 
reached clinical settings [83–88]. Proof of concept phase 2 clinical trials showed a partial efficacy of single nMAb treatment in 201 
controlling viremia due to the selection of resistant viral mutants; currently, combination of HIV-1-nMAbs with different specificities 202 
are being tested in order to avoid the emergence of virus resistance. Compared to HIV-1, SARS2 accounts for a lower mutation rate. 203 
In addition, it has not been reported that CoVs produce persistent infection and no within-host viral reservoir has been described for 204 
SARS2 or other CoVs, as for HIV-1. Altogether, these observations and the fact that in vitro neutralizing activity of SARS2 nMAbs is 205 
higher than nMAbs against Ebola and HIV-1, suggest tha passive immunization with SARS2 nMAbs could be us d to protect from 206 
COVID-19. 207 
 208 










In addition to the post-exposure treatment, nMAbs can also be used prophylactically. The first FDA-approved MAbs against 210 
infectious diseases, Palivizumab, is indicated for prevention of respiratory syncytia virus (RSV) infection in preterm infants and 211 
children at high-risk for development of severe respiratory disease [89]. For HIV-1, two large scale phase 2b clinical trials –AMP 212 
trials, enrolling 4200 participants– have been initiated to test the efficacy of prototype MAb VRC01 in preventing HIV-1 acquisition 213 
in high risk populations (NCT02716675 and NCT02568215) [90]. Several points will have to be considered if SARS2 MAbs are 214 
intended to be used prophylactically in populations at high-risk of acquiring infection or developing severe COVID-19 disease. It has 215 
been shown in animal models for HIV-1 infection that if administered pre-exposure, MAb treatment can block infection and interfere 216 
with the development of the adaptive immunity [91–93]. If this is also true for SARS2, then successive MAb doses should be 217 
administered in order to avoid the acquisition of infection, until an effective and safe method capable of inducing long-term immunity 218 
becomes available (i.e. vaccine). As a consequence of r petitive parenteral administration of an exogenous drug, anti-drug immunity 219 
can frequently decrease treatment efficacy. Althoug the use of human or fully humanized MAbs reduce such type of anti-MAb 220 
response, the constant exposure of a single MAb paratope might induce the development of anti-drug immunity.  However, such type 221 
of undesirable effect was not observed following repetitive (up to 11 doses) subcutaneous and intravenous administration of VRC01 in 222 
human volunteers as reported by Mayer and colleagues [94]. If detected in upcoming trials, such unwanted effect could be avoided by 223 
the sequential administration of nMAbs with different specificities.  224 
Importantly, antibody half-life and biodistribution could significantly impact the efficacy of the therapy. While half-lives of most 225 
antiretroviral drugs range between a few hours to 2days, the half-lives of nMAbs are measured in weeks and these periods can be 226 
further extended by modification of the antibody Fc domains that enhance the affinity to the neonatal Fc receptor (FcRn) [95]. The 227 
FcRn interacts with the Fc region of IgG and is involved in recycling of IgG within cells. This interaction is also involved in actively 228 
transporting IgGs to sites of pathogen encounter [96]. For example, the M428L and N434S (“LS”) mutations prolong antibody half-229 
life without compromising antigen-binding or other Fc-mediated functions [97]. In the case of VRC01, the FcRn enhancing mutation 230 
VRC01-LS [95] lead to 2–3 fold higher in vivo half-life in macaques compared to VRC01. In addition, increased and prolonged levels 231 
of VRC01-LS were detected in vaginal and rectal mucosal tissue compared to the unmodified VRC01 [96,97]. Recently, Griffin and 232 
colleagues showed that a single intramuscular dose of Nirsevimab protected infants for an entire RSV season [98]. Nirsevimab is 233 
engineered with a triple-amino-acid (M252Y/S254T/T256E, “YTE”) substitution within its Fc region. The YTE mutation also 234 
enhances the binding of the IgG to the FcRn prolonging the serum half-life of this antibody. 235 
Another limitation to the use of nMAbs in clinical settings is due to the fact that intravenous route employed in most nMAb clinical 236 
trials can be impractical. Subcutaneous (SC) injection, however, allows for self-administration, showing similar nMAb half-lives and 237 










half-life, may facilitate dosing every few weeks to several months for prevention. Moreover, FcRn-mediat  transport may increase 239 
the MAb levels in respiratory mucosa, where it might confer higher protection against SARS2 infection. 240 
 241 
2.3.2. Adverse events associated with MAb administration.  242 
MAbs are currently established as targeted therapies for malignancies, transplant rejection, autoimmune a d infectious diseases. 243 
Among the advantages of MAbs over conventional drugs are their high specificities, their long half-lives and their good risk–benefit 244 
ratio; moreover, regulatory approval rates for MAbs are about 20% compared with 5% for new chemical entiti s [99]. However, 245 
intravenous administration of MAbs carries the risk of immune reactions such as acute anaphylaxis, serum sickness and the generation 246 
of anti-drug antibodies. In addition, there are numerous adverse effects of MAbs that are related to their specific targets, including the 247 
development of infections and cancer, autoimmune dis ase, and organ-specific adverse events such as cardiotoxicity [100]. However, 248 
most of these adverse effects are related to the immunomodulatory effect of MAbs targeting different edogenous immune mediators 249 
(i.e., immune system checkpoints, cytokine and cytokine receptors, etc.) and are expected to be absent for MAbs targeting exogenous 250 
viral epitopes. As mentioned earlier, recent technial advances have allowed the transition from mouse, via chimeric and humanized, 251 
to fully human MAbs, with a reduction in potentially immunogenic mouse components. In addition, molecular engineering has 252 
enabled the fine-tuning of MAb function to enhance th ir effects and to minimize immunogenicity and sie effects. Remarkably, no 253 
serious adverse events were reported in several phase 1 and 2 clinical trials administering up to 11-doses of anti-HIV-1 nMAbs 254 
[87,88,94,101]. 255 
 256 
2.3.3. The challenge of increasing scale production of MAbs.  257 
An important restriction of the use of MAbs in clinical settings is related to the manufacture of large amounts of MAbs, as well as the 258 
high costs associated with it. Currently, MAb production platforms are based on the cloning of Ig-encoding genes from isolated 259 
specific-B cells. This technique involves PCR amplification of Ig-encoding genes from B cells, cloning them into an expression vector 260 
and re-expression in different mammalian cells. Batch productions can be scaled from 20-200 liters (initial phase 1-3 trials) to 12,500 261 
liters (commercial manufacturer), at an average yield of 1 g/L. For example, when Boehringer Ingelheim (Ingelheim, DE) handled the 262 
production of Palivizumab (previously done by MedImmune) they scaled up from 400 to 12.500 liter reactors, allowing a total 263 
production of 70 Kg/ year (about 560,000 standard units (SU) 120 mg each). Other example is Pembrolizumab, an anti-PD-1 MAb 264 
used for the treatment of several types of cancer; in 2019 Merk and Co. (MSD, NJ, US) produced about 200 Kg of Pembrolizumab. In 265 
the case of VRC01, used for the AMP trials, the Vaccine Research Center (VRC-NIAID, MD, US) manufactured a total of 60 Kg of 266 
MAb for administration in different treatment groups (10 mg/Kg or 30 mg/Kg; a total of 10 consecutive doses). Although the 267 










Institute of Healths (NIH, MD, US), points out that such large production scale can be achieved either by private or public sector. 269 
Most importantly, if effective, anti-SARS2 MAbs produced at those levels could save 100s thousands live . Of note, the amount of 270 
antibody necessary for treating a specific viral infectious disease will depend on the regimen of administration and the dose needed to 271 
achieve the desired antiviral activity. Such dose will be influenced by the potency and the half-life of each particular MAb. The 272 
discovery of extremely potent nMAbs against SARS2, coupled to a bioengineered upgrade (i.e., greater neutralization potency, 273 
breadth, extended half-life and proper biodistribution) will significantly reduce the number of doses and dosage needed, and most 274 
importantly, its cost.  275 
 276 
2.3.4. Clinical testing of SARS2 nMAbs.  277 
Several private companies specialized in MAb discovery and development have engaged in partnerships with government and large-278 
scale pharmaceutical companies in order to collaborate in the development, testing, cGMP clinical manuf cturing and 279 
commercialization and global distribution of several SARS2 MAbs. From a total of 89 MAbs, 14 are being tested in phase 1-3 clinical 280 
trials, for safety, tolerability and pharmacokinetics (PKs) determination. In addition, some candidates r  being tested for preliminary 281 
efficacy, with the option to extend the number of participants if preliminary data is satisfactory. Junshi Biosciences (Shangai, CN), has 282 
started a phase 1 clinical trial (NCT04441918) for JS016 (MAb CB6, Table 1) in 40 healthy patients in China. CB6 targets SARS-2 283 
RBS and specifically competes with ACE2 binding. Besid s accounting for a high neutralization potency in vitro, CB6 effectively 284 
prevented and/or controlled SARS2 infection in non-human primate (NHP) model. The company also announced an agreement with 285 
Lilly and Co (IN, US) to start the large scale production of this Ab in the US. Regeneron Pharmaceuticals (NY, US) has also 286 
announced the beginning of a series of phase 1-3 combined clinical trials with REGN-COV2 a nMAb cocktail of two nMAbs (REGN-287 
10987 and REGN-10933, Table 1). Both MAbs target different epitopes on SARS-2 RBS and compete with ACE2 binding. As 288 
reported in preclinical studies the combination of these two potently neutralizing MAbs avoided the generation of resistant viral 289 
variants in vitro. The first of these studies (NCT04426695) will engage 1860 hospitalized adults with COVID-19 to study the REGN-290 
COV2 safety, tolerability and efficacy following a single intravenous dose of the cocktail. The second stu y (NCT04425629), will test 291 
REGN-COV2 in 1054 ambulatory adult patients with COVID-19. A third study (NCT04452318) will assess the efficacy of REGN-292 
COV2 preventing SARS2 infection in household contacts of individual infected with SARS2. If preliminary esults from these trials 293 
are favorable, Regeneron plans to produce 100s thousand doses of this cocktail by the end of 2020 and also expect to produce 10 294 
Million doses during 2021. A similar approach is alo being tested by AstraZeneca (London, UK) in collaboration with Vanderbilt 295 
University Medical Center (TN, US) (COV2-2196 and COV2-2130). Another common strategy to safeguard against viral escape to 296 
antibody therapeutics involves selection of antibodes binding to conserved epitopes. In this regard, Vir Biotechnology (CA, US), in 297 










clinical trials using different SARS1/ SARS2 cross-reactive nMAbs. nMAbs VIR7831 and VIR7832, target conserved epitopes on S 299 
protein of both CoVs; mutations in Fc have been incorporated to these MAbs to extend half-life and increase FcR engagement. The 300 
company is planning to test these MAbs individually, and if effective they expect to produce 10 Million doses in 2021. Abcellera 301 
Biologics (Vancouver, CA) developed LY-COV555 (LY3819253) in collaboration with VRC-NIAID. They have rcently signed an 302 
agreement with Lilly and Co to scale up the production and commercialization of this SARS2-S protein nMAb which started phase 1 303 
clinical trial engaging 40 COVID-19 hospitalized patients (NCT04411628). In parallel they are running a phase 2 clinical trial to test 304 
MAb efficacy in 400 early mild-to-moderate COVID-19 patients (NCT04427501). The company expect to scale up the production to 305 
100s thousand doses by end 2020. More recently, Brii Biosciences LTD (Beijing, CN) launched a couple of phase 1 clinical trials, 306 
enrolling 12 participants each, to test the safety of two different antibodies administered separately: BRII196 (NCT04479631) and 307 
BRII198 (NCT04479644) (Table 1). In addition, Sinocelltech LTD (Beijing, CN) is enrolling 33 participants into a phase 1 clinical 308 
trial for nMAb SCTA01/H014 (NCT04483375) (Table 1). Furthermore, TYCHAN (SG) started a phase 1 clinial trial to test TY027 309 
MAb (NCT04429529) in 25 healthy adults and Sorrento therapeutics is doing the same with STI-1499 MAb (NCT04454398), in 24 310 
hospitalized COVID-19 patients. It is anticipated that several other anti-SARS2 nMAbs will resume clini al trials in the short future. 311 
Finally, Celltrion Healthcare (KR) announced they will start a phase 1 clinical trial to test nMAb CT-P59.  312 
 313 
 314 
2.4. CONCLUSIONS 315 
 316 
The SARS2 pandemic has caused unprecedented global health and economic damages, and the situation is not u der control yet. 317 
National Health Services worldwide, including those from the most developed countries were overwhelmed due to a high amount of 318 
severe ill patients in a reduced time-frame, and thousands of lives were lost due to unpreparedness and co troversial political 319 
decisions. Although several vaccine candidates and repurposed drugs are currently being evaluated for safety and efficacy in record 320 
time, none of them have been approved for COVID-19 use. Experts in the field agree that a vaccine will not be available in the short 321 
future; once such vaccine become available, universal accessibility has to be granted. Additionally, some populations might not 322 
respond well to it (i.e., the elderly or immunocompromised). 323 
Several nMAbs targeting different epitopes on SARS2 spike protein are being tested for the prevention and treatment of COVID-19. 324 
The combination of potent-nMAbs targeting the RBS and broad-nMAbs targeting conserved regions within the spike protein of 325 
SARS1 and SARS2 might increase treatment efficacy, by avoiding the emergence of resistant viral variants. Preclinical studies carried 326 
out in different animal models suggest that pre-exposure use of SARS2 nMAbs might prevent or at least reduce disease severity in 327 










Additionally, SARS2 nMAbs could be administered early during COVID-19 infection in those patients at hig  risk of developing 329 
severe disease, for example the elderly and patients with pre-existing conditions. By modulating acute virus replication, an early 330 
nMAb intervention in this particular population could induce a better outcome of the disease. Currently, several clinical trials have 331 
started to test the safety, tolerability, PKs and efficacy of SARS2 nMAbs using either a prophylactic or therapeutic approach. These 332 
proof-of-concept trials will inform about the importance of NAbs as a correlate of protection against SARS2 in human population. 333 
Observations from these trials will be fundamental for future clinical management of COVID-19, as well as for vaccine development. 334 
Besides the emergence of virus resistance, another paramount limitation for the use of nMAbs in clinical settings is associated with the 335 
manufacture of large amounts of MAbs and the high costs linked to it. Cooperation among public and private institutions coupled with 336 
speed of development, rapid safety and efficacy evaluation, and early planning for scale-up and manufact re will be critical for the 337 
control of COVID-19 pandemic. 338 
 339 
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TABLE 1. SARS-CoV-2 mAbs 
Specificity Name Source Isolation method Potency (IC50) Preclinical trial Clinical trial 
SARS2-RBD. Competes 
w/ACE2 binding and 
promotes S1 dissociation 
REGN-10987 60, 62, 66        
(REGN-10933)* 
SARS2-S/RBD immunized hu-
mice and COVID19 patient  
single MBC sorting (RBD bait) followed by single 
cell antibody cloning 





P2C-1F1137                        
(P2C-1C10, P2B-2FG)* 
COVID19 patient  pV: 30 ng/ml (P2C-1F11)   NA NCT04479631 (I) 
NCT04479644 (I) 
CB6-LALA 43                        
(CA1) 
  V: 36 ng/mL  Rhesus macaques NCT04441918 (I) 
 C105 47   pV: 26 ng/ml NA NA 
 C002 30                         
(C121)* 
  V: 10 ng/ml NA NA 
 nAB cc12.1 38                             
(nAB c12.23) 
  V: 19 ng/ml (cc12.1)  Syrian hamsters NA 
 B38 42                                             
(H4)* 
  V: 200 ng/ml  hACE2-transgenic mice NA 
 311mAb-31B5 48                  
(32D4) 
    pV: 50 ng/ml NA NA 
 COVA1-18 61                    
(COVA2-15, COVA2-17)* 
COVID19 patient single MBC sorting (stabilized pre-fusion SARS2-
S bait) followed by single cell antibody cloning 
RBD mAbs pV: 7 ng/ml NA NA 
 CV30 58                                        
(CV1)* 
    pV: 30 ng/ml (CV30) and 
15000 ng/ml (CV1)  
NA NA 
 COV2-2196 59                       
(COV2-2130) 
COVID19 patient single MBC sorting (SARS2-S bait) followed by 
single cell antibody cloning 
V: 1-10 ng/ml hACE2-expressing mice 
(AdV-hACE2 transduction) 
NA 
  BD-368-2 49  single-cell RNA (VDJ) sequencing of antigen 
(RBD & S)-enriched B cells 
V: 15 ng/mL   hACE2-transgenic mice NA 
SARS2-S NTD, without 
competing ACE2 binding  
4A8 51 COVID19 patient single MBC plasmablasts sorting (SARS2 
stabilized spike-derived ectodomain bait) followed 
by single cell antibody cloning 




competing ACE2 binding 
CR3022 52, 53, 63 SARS1 patient  SARS1-reactive mAb selected from a single-chain 
Fv phage display library econstructed into IgG1 
format 
V: 114 ng/mL NA NA 
47D11-H2L2 54 SARS1 S hybridoma's derived 
from immunized transgenic H2L2 
mice 
suppernantant screening for reactivity against 
SARS2-S1 by ELISA and SARS2 pV 
neutralization 
V: 570 ng/ml NA NA 
S309 55 Inmortalized memory B cells from 
SARS1 patient 
suppernantant screening for reactivity against 
SARS-CoV-2 S by ELISA 
V: 79 ng/ml  NA NA 
Cross-neutralization 
SARS1/SARS2. RBD 
attachmen competing with 
ACE2 binding and 
promoting S1 dissociation 
H014 64 mice immunized with SARS1 
RBD 
phage display panning using SARS2 RBD V: 38 ng/mL hACE2-transgenic mice NCT04483375 (I) 
ADI55689 56                  
(ADI56046)* 
PBMCs from SARS1 infected 
patient 
single MBC sorting (RBD bait) followed by single 
cell antibody cloning 
V: 50-1400 ng/ml  NA NA 
VHH72-Fc 57 llama immunized with prefusion-
stabilized CoV S 
phage display panning using SARS1 or MERS S 
proteins 
Two VHH coupled as a 
bi-valent IgG-Fc fusion 
needed for neutralization  
NA NA 
* : 2 or more different epitopes 661 
pV: pseudovirus assay was used to determine neutraliza ion potency 662 
V: authentic live virus was used to determine neutralization potency 663 










NA: not assayed  665 
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